US FDA clears CMR Surgical's robotic device to assist gall bladder removal
Oct 15 (Reuters) -UK-based medical device maker CMR Surgical said on Tuesday that the U.S. Food and Drug Administration has cleared the upgraded version of its surgical robot to be used in gall bladder removal procedures.
The portable device, called Versius Surgical System, was cleared for use in patients aged 22 years and older who are eligible for minimally invasive surgery, the company said.
CMR Surgical did not disclose its commercialization plans and pricing details for the U.S., but said it expects the total cost to be "favorable."
"This is a significant opportunity and CMR is confident that by addressing a gap in the market Versius can be a successful product in the U.S.," the company said.
CMR said it plans to initially partner with a select number of U.S. hospitals before expanding nationwide.
The device has been cleared through the FDA's De Novo application process, which provides a marketing pathway to classify novel medical devices that have no legally marketed equivalent or predicate device.
The device had also secured European Union's CE mark in 2019.
Reporting by Mariam Sunny in Bengaluru; Editing by Alan Barona
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
